Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

3271 - Circulating microRNA-126 and epidermal growth factor-like domain 7 protein predict recurrence of colon cancer in patients treated with neoadjuvant chemotherapy


08 Oct 2016


Poster Display


Torben Hansen


Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370


T.F. Hansen1, A.L. Carlsen2, J.T. Tanassi2, N.H..H. Hegaard2, F.O. Larsen3, F.B. Soerensen4, L.H. Jensen1, A. Jakobsen1

Author affiliations

  • 1 Oncology, Danish Colorectal Cancer Center South, 7100 - Vejle/DK
  • 2 Autoimmunology And Biomarkers, Statens Serum Institut, Copenhagen/DK
  • 3 Department Of Oncology, Herlev and Gentofte Hospital, 2730 - Herlev/DK
  • 4 Clinical Pathology, Danish Colorectal Cancer Center South, 7100 - Vejle/DK


Abstract 3271


Neoadjuvant chemotherapy represents a new treatment approach for patients with locally advanced colon cancer. The aim of this study was to analyze the prognostic impact of circulating microRNA-126 (miRNA-126) and epidermal growth factor-like domain 7 (EGFL7) in patients with locally advanced colon cancer treated with neoadjuvant chemotherapy.


All 71 patients from a phase II trial were included. Sampling of peripheral blood was carried out before initiation of neoadjuvant chemotherapy, before operation, and at the first post-operative control. The diagnostic biopsy and the resected tumour were sampled for tissue analyses. Circulating (cir-) EGFL7 was analysed in serum by enzyme-linked immunosorbent assay (ELISA) while cir-miRNA-126 was analysed by real-time qPCR based on plasma samples. The tissue expression of miRNA-126 was assessed using in situ hybridization and image guided analyses.


After a median follow-up of 4.0 years, disease had recurred in 14 patients. The 5-year disease free survival (DFS) and overall survival (OS) rates were 80% and 85%, respectively. Overall, cir-miRNA-126 and cir-EGFL7 decreased during neoadjuvant chemotherapy. Patients with disease recurrence were characterized by a significantly lower miRNA-126 expression in the diagnostic biopsy (p = 0.049), and significantly lower levels of cir-miRNA-126 at baseline (p = 0.020), operation (p = 0.042), and control (p = 0.001), compared to patients without disease recurrence. High levels of cir-EGFL7, assessed before operation, were associated with a higher recurrence rate (p = 0.019). These differences translated into significant differences in DFS and OS as well. A 5-year OS rate of 96% was demonstrated for patients with cir-miRNA-126 levels above the median.


Low levels of miRNA-126 and high levels of EGFL7 seem to correlate with disease recurrence in patients with locally advanced colon cancer treated with neoadjuvant chemotherapy. These results are in accordance with previous studies in the adjuvant and metastatic setting collectively arguing for a clinical importance of these proangiogenic factors.

Clinical trial identification

ClinicalTrials.gov Identifier:NCT01108107

Legal entity responsible for the study

Department of Oncology, Vejle Hospital


Department of Oncology, Vejle Hospital


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings